Rosiglitazone (BRL49653), a PPARγ-selective agonist, causes peroxisome proliferator-like liver effects in obese mice

Journal of Lipid Research

Volumn 40, Issue 7, 1999, Pages 1177-1184

  Edvardsson, Ulrika ^a   Bergström, Monica ^a   Alexandersson, Maria ^a   Bamberg, Krister ^a   Ljung, Bengt ^a   Dahllöf, Björn ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

BRL49653; Insulin resistance; ob ob; Obese mice; Peroxisome proliferation; PPAR; Proteomies; Two dimensional gel electrophoresis; WY14,643

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIRINIXIC ACID; ROSIGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CELL RECEPTOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FATTY ACID OXIDATION; LEAN BODY WEIGHT; LIVER; MOUSE; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; DRUG EFFECT; MALE; METABOLISM; MOUSE MUTANT; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HYPOGLYCEMIC AGENTS; LIVER; MALE; MICE; MICE, OBESE; OBESITY; PEROXISOME PROLIFERATORS; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0032587268     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wahli, W., O. Braissant, and B. Desvergne. 1995. Peroxisome proliferator activated receptors-transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol. 2: 261-266.
2. Schoonjans, K., B. Staels, and J. Auwerx. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925.
3. Spiegelman, B. M. 1998. PPAR-gamma - adipogenic regulator and thiazolidinedione receptor. Diabetes. 47: 507-514.
4. Issemann, I., and S. Green. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347: 645-650.
5. Tontonoz, P., E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman. 1994. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes & Dev. 8: 1224-1234.
6. Braissant, O., F. Foufelle, C. Scotto, M. Dauca, and W. Wahli. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs) - tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 137: 354-366.
7. Fajas, L., J. C. Fruchart, and J. Auwerx. 1998. PPAR-gamma-3 mRNA - a distinct PPAR-gamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 438: 55-60.
8. Yu, K., W. Bayona, C. B. Kallen, H. P. Harding, C. P. Ravera, G. McMahon, M. Brown, and M. A. Lazar. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270: 23975-23983.
9. Forman, B. M., P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans. 1995. 15-Deoxy-delta(12,14)-prostaglandin J(2) is a ligand for the adipocyte determination factor PPAR-gamma. Cell. 83: 803-812.
10. Forman, B. M., J. Chen, and R. M. Evans. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci USA. 94: 4312-4317.
11. Devchand, P. R., H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli. 1996. The PPAR-alpha-leukotriene B-4 pathway to inflammation control. Nature. 384: 39-43.
12. Kliewer, S. A., J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann. 1995. A prostaglandin J(2) metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83: 813-819.
13. Issemann, I., R. A. Prince, J. D. Tugwood, and S. Green. 1993. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 11: 37-47.
14. Frøyland, L., L. Madsen, H. Vaagenes, G. K. Totland, J. Auwerx, H. Kryvi, B. Staels, and R. K. Berge. 1997. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J. Lipid Res. 38: 1851-1858.
15. Simpson, A. 1997. The cytochrome P450 4 (CYP4) family. Gen. Pharmacol. 28: 351-359.
16. Schoonjans, K., J. Peinadoonsurbe, A. M. Lefebvre, R. A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx. 1996. PPAR-alpha and PPAR-gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15: 5336-5348.
17. Hiragun, A., M. Sato, and H. Mitsui. 1988. Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent. J. Cell. Physiol. 134: 124-130.
18. Kletzien, R. F., S. D. Clarke, and R. G. Ulrich. 1992. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41: 393-398.
19. Tontonoz, P., E. D. Hu, and B. M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79: 1147-1156.
20. Brun, R. P., P. Tontonoz, B. M. Forman, R. Ellis, J. Chen, R. M. Evans, and B. M. Spiegelman. 1996. Differential activation of adipogenesis by multiple PPAR isoforms. Genes & Dev. 10:974-984.
21. Young, P. W., M. A. Cawthorne, P. J. Coyle, J. C. Holder, G. D. Holman, I. J. Kozka, D. M. Kirkham, C. A. Lister, and S. A. Smith. 1995. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes. 44: 1087-1092.
22. Hallakou, S., L. Doare, F. Foufelle, M. Kergoat, M. Guerre-Millo, M. F. Berthault, I. Dugail, J. Morin, J. Auwerx, and P. Ferre. 1997. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker Fa/Fa rat. Diabetes. 46: 1393-1399.
23. Chang, A. Y., B. M. Wyse, and B. J. Gilchrist. 1983. Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. Diabetes. 32: 839-845.
24. Hofmann, C., K. Lorenz, S. S. Braithwaite, J. R. Colca, B. J. Palazuk, G. S. Hotamisligil, and B. M. Spiegelman. 1994. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology. 134: 264-270.
25. Macdougald, O. A., C. S. Hwang, H. Y. Fan, and M. D. Lane. 1995. Regulated expression of the obese gene product (Leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA. 92: 9034-9037.
26. Zhang, B., M. P. Graziano, T. W. Doebber, M. D. Leibowitz, S. White-Carrington, D. M. Szalkowski, P. J. Hey, M. Wu, C. A. Cullinan, P. Bailey, B. Lollmann, R. Frederich, J. S. Flier, C. D. Strader, and R. G. Smith. 1996. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J. Biol. Chem. 271: 9455-9459.
27. Rentsch, J., and M. Chiesi. 1996. Regulation of ob gene mRNA levels in cultured adipocytes. FEBS Lett. 379: 55-59.
28. Staels, B., N. Vudac, V. A. Kosykh, R. Saladin, J. C. Fruchart, J. Dallongeville, and J. Auwerx. 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme a oxidase - a potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95: 705-712.
29. Hertz, R., J. Bisharashieban, and J. Bartana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs - suppression of apolipoprotein C-III. J. Biol. Chem. 270: 13470-13475.
30. Ashby, J., A. Brady, C. R. Elcombe, B. M. Elliott, J. Ishmael, J. Odum, J. D. Tugwood, S. Kettle, and I. F. Purchase. 1994. Mechanistically based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13: S1-117.
31. Colca, J. R., and D. R. Morton. 1990. Antihyperglycaemic thiazolidinediones: ciglitazone and its analogues. In New Antidiabetic Drugs. C. J. Bailey and P. R. Flatt, editors. Eldered Smith-Gordon, London. 255-261.
32. Cantello, B. C. C., M. A. Cawthorne, G. P. Cottam, P. T. Duff, D. Haigh, R. M. Kindley, C. A. Lister, S. A. Smith, and P. L. Thurlby. 1994. [[Omega-(heterocyclylamino)alkoxy]benzyl]-2, 4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. 37: 3977-3985.
33. Lehmann, J. M., L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR-gamma). J. Biol. Chem. 270: 12953-12956.
34. Johnson, M. D., L. K. Campbell, and R. K. Campbell. 1998. Troglitazone - review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann. Pharmacother. 32: 337-348.
35. Patel, J., E. Miller, and R. Patwardhan. 1998. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Diabetes. 47: A17.
36. Edvardsson, U., M. Alexandersson, F. Nilsson, H. Brockenhuus von Löwenhielm, A-C. Nyström, B. Ljung, and B. Dahllöf. 1999. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643. Electrophoresis. 20: 935-942.
37. Görg, A., G. Boguth, C. Obermaier, A. Posch, and W. Weiss. 1995. Two-dimensional polyacrylamide gel electrophoresis with immobilized pH gradients in the first dimension (IPG-Dalt): the state of the art and the controversy of vertical versus horizontal systems. Electrophoresis. 16: 1079-1086.
38. Shevchenko, A., M. Wilm, O. Vorm, and M. Mann. 1996. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68: 850-858.
39. Garrels, J. I. 1989. The QUEST system for quantitative analysis of two-dimensional gels. J. Biol. Chem. 264: 5269-5282.
40. Vidalpuig, A., M. Jimenezlinan, B. B. Lowell, A. Hamann, E. Hu, B. Spiegelman, J. S. Flier, and D. E. Moller. 1996. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97: 2553-2561.
41. Costet, P., C. Legendre, J. More, A. Edgar, P. Galtier, and T. Pineau. 1998. Peroxisome proliferator-activated receptor α-isoform defiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273: 29577-29585.